Clay ingestion enhances intestinal triacylglycerol hydrolysis and non-esterified fatty acid absorption.
Consumption by animals and humans of earthy materials such as clay is often related to gut pathologies. Our aim was to determine the impact of kaolinite ingestion on glucose and NEFA transport through the intestinal mucosa. The expression of hexose transporters (Na/glucose co-transporter 1 (SGLT1), GLUT2, GLUT5) and of proteins involved in NEFA absorption (fatty acid transporter/cluster of differentiation 36 (FAT/CD36), fatty acid transport protein 4 (FATP4) and liver fatty acid binding protein (L-FABP)) was measured (1) in rats whose jejunum was perfused with a solution of kaolinite, and (2) in rats who ate spontaneously kaolinite pellets during 7 and 28 d. Also, we determined TAG and glucose absorption in the kaolinite-perfused group, and pancreatic lipase activity, gastric emptying and intestinal transit in rats orally administered with kaolinite. Glucose absorption was not affected by kaolinite perfusion or ingestion. However, kaolinite induced a significant increase in intestinal TAG hydrolysis and NEFA absorption. The cytoplasmic expression of L-FABP and FATP4 also increased due to kaolinite ingestion. NEFA may enter the enterocytes via endocytosis mainly since expression of NEFA transporters in the brush-border membrane was not affected by kaolinite. After uptake, rapid binding of NEFA by L-FABP and FATP4 could act as an intracellular NEFA buffer to prevent NEFA efflux. Increased TAG hydrolysis and NEFA absorption may be due to the adsorption properties of clay and also because kaolinite ingestion caused a slowing down of gastric emptying and intestinal transit.
Habold
Caroline
C
Institut Pluridisciplinaire Hubert Curien, UMR 7178 CNRS-ULP, 23 Rue du Loess, BP28, 67037 Strasbourg Cedex 2, France. caroline.habold@c-strasbourg.fr
Reichardt
François
F
Le Maho
Yvon
Y
Angel
Fabielle
F
Liewig
Nicole
N
Lignot
Jean-Hervé
JH
Oudart
Hugues
H
D000284:Administration, Oral; D000818:Animals; D000930:Antidiarrheals / Q000008:administration & dosage*; D050612:Fatty Acid Transport Proteins / Q000235:genetics; D050556:Fatty Acid-Binding Proteins / Q000235:genetics; D005230:Fatty Acids, Nonesterified / Q000378:metabolism*; D005746:Gastric Emptying / Q000502:physiology; D005772:Gastrointestinal Transit; D005947:Glucose / Q000378:metabolism; D051296:Glucose Transporter Type 5 / Q000235:genetics; D006868:Hydrolysis; D007408:Intestinal Absorption / Q000502:physiology*; D007413:Intestinal Mucosa / Q000378:metabolism*; D007616:Kaolin / Q000008:administration & dosage*; D008049:Lipase / Q000032:analysis; D008297:Male; D012333:RNA, Messenger / Q000032:analysis; D051381:Rats; D017208:Rats, Wistar; D051269:Sodium-Glucose Transporter 1 / Q000235:genetics; D014280:Triglycerides / Q000032:analysis / Q000378:metabolism*
D000930:Antidiarrheals; D050612:Fatty Acid Transport Proteins; D050556:Fatty Acid-Binding Proteins; D005230:Fatty Acids, Nonesterified; D051296:Glucose Transporter Type 5; D012333:RNA, Messenger; C542875:Slc27a4 protein, rat; D051269:Sodium-Glucose Transporter 1; D014280:Triglycerides; D007616:Kaolin; D008049:Lipase; D005947:Glucose